Ixazomib

Drug Profile

Ixazomib

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Takeda Oncology; University of Leeds; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Organic boron compounds; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Follicular lymphoma; Haematological malignancies; Myelodysplastic syndromes; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Graft-versus-host disease
  • Phase I Acute lymphoblastic leukaemia; Lupus nephritis; Lymphoma; Solid tumours

Most Recent Events

  • 24 Nov 2016 Registered (Conditional approval) for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Liechtenstein, Iceland, Norway, European Union (PO)
  • 24 Nov 2016 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (PO)
  • 01 Nov 2016 Millennium Pharmaceuticals completes a phase I/Ib trial in multiple myeloma and advanced solid tumour in Canada and USA (NCT01830816)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top